What does VEROVIR PHARMA do?

VEROVIR PHARMA is a bank in Charleroi. Public Limited, started on 31 March 1994, 1 establishment.

What is the address of VEROVIR PHARMA?

The registered office of VEROVIR PHARMA is located at Rue du Gallois 2G, 6032 Charleroi.

Is VEROVIR PHARMA still active?

Yes. According to the CBE (31 October 2026) VEROVIR PHARMA is active, legal situation “Normale toestand”, started on 31 March 1994.

Is VEROVIR PHARMA registered on Peppol?

Yes, VEROVIR PHARMA is registered on the Peppol network with ID 0208:0452353263.

What is the enterprise number of VEROVIR PHARMA?

The enterprise number of VEROVIR PHARMA is BE0452353263.

When was VEROVIR PHARMA founded?

VEROVIR PHARMA was founded on 31 March 1994.

Who are the directors of VEROVIR PHARMA?

According to the 2025 annual accounts, the directors of VEROVIR PHARMA are: HENRI LEDOUX.

Is VEROVIR PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 31 March 1994; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did VEROVIR PHARMA make in 2025?

VEROVIR PHARMA posted a profit after taxes of € 49,471 in financial year 2025.

What is the revenue of VEROVIR PHARMA?

As a small company, VEROVIR PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 154,027.

VEROVIR PHARMA (Public Limited) - Charleroi

Dossier VEROVIR PHARMA, printed on 31 October 2026 from databakkes.be/en/0452353263/verovir-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

VEROVIR PHARMA from Charleroi, company number BE0452353263, closed financial year 2025 with a result of € 49,471 after tax. For that financial year VEROVIR PHARMA recorded a gross margin of € 154,027 and equity of € 1 million. Compared with financial year 2024, the result moved from € 22,556 to € 49,471. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 10, 2026.

What it is worth Growing

€ 1 million

▲ 5% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 49,471

▲ 119% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 420,278

▲ € 325,403 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 806,732.

Debts at end 2025

Bank debt

€ 700

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 3,340

▲ 33% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,566

▼ 19% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 108,481 Gross margin 2022: € 108,481 First fiscal year in the series	€ 70,355 Gross margin 2023: € 70,355 ▼ 35% vs 2022 (€ 108,481) Unfavourable step	€ 91,061 Gross margin 2024: € 91,061 ▲ 29% vs 2023 (€ 70,355) Favourable step	€ 154,027 Gross margin 2025: € 154,027 ▲ 69% vs 2024 (€ 91,061) Favourable step	▲ 69%
Profit after taxes	€ 39,415 Profit after taxes 2022: € 39,415 First fiscal year in the series	€ 5,582 Profit after taxes 2023: € 5,582 ▼ 86% vs 2022 (€ 39,415) Unfavourable step	€ 22,556 Profit after taxes 2024: € 22,556 ▲ € 16,974 vs 2023 (€ 5,582) Favourable step	€ 49,471 Profit after taxes 2025: € 49,471 ▲ 119% vs 2024 (€ 22,556) Favourable step	▲ 119%
Equity	€ 927,524 Equity 2022: € 927,524 First fiscal year in the series	€ 933,105 Equity 2023: € 933,105 ▲ 1% vs 2022 (€ 927,524) Favourable step	€ 955,661 Equity 2024: € 955,661 ▲ 2% vs 2023 (€ 933,105) Favourable step	€ 1,005,132 Equity 2025: € 1,005,132 ▲ 5% vs 2024 (€ 955,661) Favourable step	▲ 5%
Total debts	€ 6,292 Total debts 2022: € 6,292 First fiscal year in the series	€ 11,344 Total debts 2023: € 11,344 ▲ 80% vs 2022 (€ 6,292) Unfavourable step	€ 14,087 Total debts 2024: € 14,087 ▲ 24% vs 2023 (€ 11,344) Unfavourable step	€ 11,739 Total debts 2025: € 11,739 ▼ 17% vs 2024 (€ 14,087) Favourable step	▼ 17%
Cash	€ 198,328 Cash 2022: € 198,328 First fiscal year in the series	€ 247,906 Cash 2023: € 247,906 ▲ 25% vs 2022 (€ 198,328) Favourable step	€ 94,875 Cash 2024: € 94,875 ▼ 62% vs 2023 (€ 247,906) Unfavourable step	€ 420,278 Cash 2025: € 420,278 ▲ € 325,403 vs 2024 (€ 94,875) Favourable step	▲ € 325,403
Land & buildings	€ 530,818 Land & buildings 2022: € 530,818 First fiscal year in the series	€ 504,641 Land & buildings 2023: € 504,641 ▼ 5% vs 2022 (€ 530,818) Unchanged	€ 480,834 Land & buildings 2024: € 480,834 ▼ 5% vs 2023 (€ 504,641) Unchanged	€ 454,471 Land & buildings 2025: € 454,471 ▼ 5% vs 2024 (€ 480,834) Unchanged	▼ 5%
Retained profit	€ 729,124 Retained profit 2022: € 729,124 First fiscal year in the series	€ 734,705 Retained profit 2023: € 734,705 ▲ 1% vs 2022 (€ 729,124) Favourable step	€ 757,261 Retained profit 2024: € 757,261 ▲ 3% vs 2023 (€ 734,705) Favourable step	€ 806,732 Retained profit 2025: € 806,732 ▲ 7% vs 2024 (€ 757,261) Favourable step	▲ 7%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 700 Bank debt 2025: € 700 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 933,815 Balance sheet total 2022: € 933,815 First fiscal year in the series	€ 944,449 Balance sheet total 2023: € 944,449 ▲ 1% vs 2022 (€ 933,815) Unchanged	€ 969,748 Balance sheet total 2024: € 969,748 ▲ 3% vs 2023 (€ 944,449) Unchanged	€ 1,016,871 Balance sheet total 2025: € 1,016,871 ▲ 5% vs 2024 (€ 969,748) Unchanged	▲ 5%

Key figures of VEROVIR PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to VEROVIR PHARMA?

What happened at VEROVIR PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 10, 2026 New annual accounts for financial year 2025: profit of € 49,471 (▲ 119% vs 2024). Source: NBB ↗
May 27, 1999 New establishment in Charleroi. KBO
Mar 31, 1994 Start of the company according to the CBE. KBO
1994 HENRI LEDOUX became a director. NBB

In short

From € 39,415 profit in 2022 to € 49,471 profit in 2025.

Paid € 40,225 in corporate taxes since 2022.

Best year ever: 2025, with € 49,471 profit.

Original PDFs at the National Bank ↗

Management

HENRI LEDOUX

VEROVIR PHARMA

Behind VEROVIR PHARMA is HENRI LEDOUX.

Directors

According to the 2025 annual accounts

HENRI LEDOUX

Director

since 1994

Establishments

Establishment units

Physical locations of this company

Registered office

Rue du Gallois 2G

6032 Charleroi

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0452.353.263
VAT number: BE 0452.353.263
Registered office: Rue du Gallois 2G, 6032 Charleroi
Names & denominations: VEROVIR PHARMA
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 31 March 1994
Peppol: Active · Active since 22 Dec 2025
Activities · NACE: Overige activiteiten van geldscheppende financiële instellingen

View on CBE Public ↗ Annual accounts (NBB) ↗